|
[1]Jolivet-Reynaud C, Adida A, Michel S, et al.Characterization ofmimotopes mimicking an immunodominant conformational epitope onthe hepatitis C virus NS3 helicase[J].J Med Virol, 2004, 72 (3) :385-395.
|
|
[2]Mondelli MU, Cerino A, Boender P, et al.Significance of the im-mune response to a major, conformational B-cell epitope on thehepatitis C virus NS3 region defined by a human monoclonal anti-body[J].J Virol, 1994, 68 (8) :4829-4836.
|
|
[3]Tobler LH, Stramer SL, Chien DY, et al.Antibodies to a novel an-tigen in acute hepatitis C virus infections[J].Vox Sang, 2007, 92 (1) :1-7.
|
|
[4]Cavazza S, Lagging M.Indeterminate third-generation hepatitis Crecombinant immunoblot assay and HCV RNA analysis:isolated re-activity against NS5 associated with HCV viraemia in clinical pa-tients but not blood donors[J].Scand J Infect Dis, 2005, 37 (6-7) :488-492.
|
|
[5]Colin C, Lanoir D, Touzet S, et al.Sensitivity and specificity ofthird-generation hepatitis C virus antibody detection assays:anan-alysis of the literature[J].J Viral Hepat, 2001, 8 (2) :87-95.
|
|
[6]Dufour DR, Talastas M, Fernandez MD, et al.Low-positive anti-hepatitis C virus enzyme immunoassay results:an important pre-dictor of low likelihood of hepatitis C infection[J].Clin Chem, 2003, 49 (3) :479-486.
|
|
[7]Alter MJ, Kuhnert WL, Finelli L.Guidelines for laboratory testingand result reporting of antibody to hepatitis C virus.Centers for Dis-ease Control and Prevention[J].MMWR Recomm Rep, 2003, 52 (RR-3) :1-13.
|
|
[8]Oethinger M, Mayo DR, Falcone J, et al.Efficiency of the orthoVITROS assay for detection of hepatitis C virus-specific antibodiesincreased by elimination of supplemental testing of samples with verylow sample-to-cutoff ratios[J].J Clin Microbiol, 2005, 43 (5) :2477-2480.
|
|
[9]任芙蓉, 龚晓燕, 李京京, 等.献血员丙型肝炎病毒抗体酶免疫法检测试剂的测量值与其真阳性的相关性[J].中华肝脏病杂志, 2005, 13 (4) :255-258.
|
|
[10]Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, manage-ment, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.
|
|
[11]NIH Consensus Statement on Management of Hepatitis C:2002[J].NIH Consens State Sci Statements, 2002, 19 (3) :1-46.
|
|
[12]张瑞, 李金明.丙型肝炎病毒感染临床检测程序的建立及结果报告与解释[J].中华检验医学杂志, 2010, 33 (10) :990-992.
|
|
[13]Saldanha J, Lelie N, Heath A.Establishment of the first interna-tional standard for nucleic acid amplification technology (NAT) as-says for HCV RNA.WHO Collaborative Study Group[J].VoxSang, 1999, 76 (3) :149-158.
|
|
[14]Saldanha J, Heath A, Aberham C, et al.World Health Organiza-tion collaborative study to establish a replacement WHO internation-al standard for hepatitis C virus RNA nucleic acid amplificationtechnology assays[J].Vox Sang, 2005, 88 (3) :202-204.
|
|
[15]王露楠, 吴健民, 李金明, 等.丙型肝炎病毒核酸检测的国家标准物质的研制[J].中华检验医学杂志, 2006, 29 (4) :354-358.
|
|
[16]Beld M, Sentjens R, Rebers S, et al.Performance of the New Ba-yer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis Cvirus RNA in plasma and serum:conversion to international unitsand comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay[J].J Clin Microbiol, 2002, 40 (3) :788-793.
|
DownLoad: